PT82164B - Process for the preparation of new cyclosporines - Google Patents

Process for the preparation of new cyclosporines

Info

Publication number
PT82164B
PT82164B PT82164A PT8216486A PT82164B PT 82164 B PT82164 B PT 82164B PT 82164 A PT82164 A PT 82164A PT 8216486 A PT8216486 A PT 8216486A PT 82164 B PT82164 B PT 82164B
Authority
PT
Portugal
Prior art keywords
residue
formula
mebmt
cyclosporins
protonated
Prior art date
Application number
PT82164A
Other languages
Portuguese (pt)
Other versions
PT82164A (en
Inventor
Dieter Seebach
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27262613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT82164(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB858506230A external-priority patent/GB8506230D0/en
Priority claimed from GB858511029A external-priority patent/GB8511029D0/en
Priority claimed from GB868602370A external-priority patent/GB8602370D0/en
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of PT82164A publication Critical patent/PT82164A/en
Publication of PT82164B publication Critical patent/PT82164B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/19—Antibiotic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Cyclosporins e.g. of formula IIin whichX is -MeBmt- or -dihydro-MeBmt- andY is -aAbu-, Thr-, -Val- or -Nva-, wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, a-N-methylated a-aminoacid residue of the (D)-configuration, possess pharmaceutical, in particular immunosuppressive, anti-inflammatory and anti-parasitic activity. Intermediate cyclosporin poly-anions having a de-protonated sarcosyl residue at the 3-position, e.g. polyanions of cyclosporins of formula II above wherein X and Y have the meanings given above and Z is -Sar<sub>-</sub>, in which the said residue Z is de-protonated, are also novel and part of the invention.
PT82164A 1985-03-11 1986-03-10 Process for the preparation of new cyclosporines PT82164B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB858506230A GB8506230D0 (en) 1985-03-11 1985-03-11 Organic compounds
GB858511029A GB8511029D0 (en) 1985-05-01 1985-05-01 Organic compounds
GB868602370A GB8602370D0 (en) 1986-01-31 1986-01-31 Organic compounds

Publications (2)

Publication Number Publication Date
PT82164A PT82164A (en) 1986-04-01
PT82164B true PT82164B (en) 1988-01-04

Family

ID=27262613

Family Applications (1)

Application Number Title Priority Date Filing Date
PT82164A PT82164B (en) 1985-03-11 1986-03-10 Process for the preparation of new cyclosporines

Country Status (16)

Country Link
US (2) US4703033A (en)
EP (1) EP0194972B1 (en)
JP (1) JPH0759594B2 (en)
KR (1) KR860007285A (en)
AT (1) ATE78832T1 (en)
AU (1) AU588860B2 (en)
DE (1) DE3686183T2 (en)
DK (1) DK109486A (en)
ES (2) ES8900141A1 (en)
FI (1) FI860993A (en)
GR (1) GR860646B (en)
HU (1) HUT47137A (en)
IL (1) IL78083A0 (en)
NZ (1) NZ215414A (en)
PH (1) PH22439A (en)
PT (1) PT82164B (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) * 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
EP0296122B1 (en) * 1987-06-17 1993-09-29 Sandoz Ag Cyclosporins and their use as pharmaceuticals
EP0373260B1 (en) * 1987-06-22 1994-03-09 Merck & Co. Inc. Cyclosporin derivatives with modified "8-amino acid"
GB2206119B (en) * 1987-06-22 1990-10-31 Merck & Co Inc A new cyclosporin derivative with modified "8-amino acid"
US5227467A (en) * 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
GB2207678A (en) * 1987-08-03 1989-02-08 Merck & Co Inc Novel immunosuppressive fluorinated cyclosporin analogs
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
EP0391909B1 (en) * 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4914188A (en) * 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US5271935A (en) * 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
GB2227244A (en) * 1989-01-19 1990-07-25 Merck & Co Inc Immunosuppressive fluorinated cyclosporin analogs
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5214130A (en) * 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5202310A (en) * 1990-06-06 1993-04-13 Levy Gary A Cyclosporine metabolites
ES2095926T5 (en) * 1990-11-02 2001-02-16 Novartis Ag CYCLOSPORINS
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US5639852A (en) * 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5948693A (en) * 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
WO1997004005A2 (en) * 1995-07-17 1997-02-06 C-Chem Ag Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (en) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド Inhibitors of cyclophilin rotamase activity
FR2757522B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2757520B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2757521B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2762843B1 (en) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
DK0991660T3 (en) 1997-10-08 2006-02-13 Isotechnika Inc Deuterated and unutilized cyclosporin analogs and their use as immunomodulatory agents
FR2772768B1 (en) * 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES
PT1086124E (en) 1998-06-12 2004-04-30 Chem Ag C NEW CYCLOSPORINS
FR2780061B1 (en) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES
USRE40987E1 (en) 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
EP1214293A1 (en) 1999-09-08 2002-06-19 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
WO2002042259A2 (en) * 2000-11-27 2002-05-30 University Of Maryland, Baltimore Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
KR100465012B1 (en) * 2001-05-11 2005-01-13 주식회사 엘지생활건강 Use of 3-position cyclosporin derivatives for hair growth
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
AR036852A1 (en) 2001-10-19 2004-10-06 Isotechnika Inc PRE-CONCENTRATED OF A MICROEMULSION OF CYCLOSPORINE ANALOGS, ITS PREPARATION METHOD AND METHODS TO PRODUCE IMMUNOSUPPRESSION
KR100982466B1 (en) 2001-10-19 2010-09-16 이소테크니카 인코포레이티드 Synthesis of cyclosporin analogs
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (en) * 2002-11-04 2004-05-12 주식회사 엘지생활건강 Use of 3-position cyclosporin derivatives for hair growth
WO2004082629A2 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
US20080039377A1 (en) * 2004-04-08 2008-02-14 Applied Research Systems Ars Holding N.V. Composition Comprising a Jnk Inhibitor and Cyclosporin
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060035821A1 (en) * 2004-08-16 2006-02-16 Hunt Kevin W Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
EP1804823A4 (en) * 2004-09-29 2010-06-09 Amr Technology Inc Novel cyclosporin analogues and their pharmaceutical uses
EP1809656A4 (en) * 2004-09-29 2009-03-25 Amr Technology Inc Cyclosporin alkyne analogues and their pharmaceutical uses
BRPI0516737A (en) * 2004-10-01 2008-04-29 Scynexis Inc method for treating or preventing hepatitis c virus infection, uses of a cyclosporine derivative and 3 - [(r) -2- (n, n-dimethylamino) ethylthio-sar] -4- (gamma-hydroxymethylucine) cyclosporine , or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the cyclosporin derivative, and hydrate
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006041631A2 (en) * 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
ATE498630T1 (en) * 2005-09-30 2011-03-15 Scynexis Inc ARYLALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORIN A IN THE TREATMENT AND PREVENTION OF VIRUS INFECTION
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
CN101502196A (en) * 2006-06-02 2009-08-05 克洛德·安妮·佩里西恩 Management of active electrons
US20080206287A1 (en) * 2006-09-18 2008-08-28 Reed John C Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
US7576057B2 (en) * 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
US9090671B2 (en) * 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
WO2010076329A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
RU2492181C2 (en) * 2009-01-30 2013-09-10 Энанта Фармасьютикалс, Инк. Cyclosporin analogues for prevention or treatment of hepatite c infection
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CA2763207A1 (en) 2009-05-27 2010-12-02 Allergan, Inc. Cyclosporin derivatives for treating inflammatory diseases and conditions
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
EP2509615A1 (en) * 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012009715A2 (en) 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012021796A2 (en) 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
RU2013119869A (en) 2010-10-12 2014-11-20 Аллерган, Инк. ANALOGUES OF CYCLOSPORIN
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
DK2646043T3 (en) * 2010-12-03 2017-05-22 S&T Global Inc HIS UNKNOWN CYCLOSPORINE DERIVATIVES FOR TREATMENT AND PREVENTION OF A VIRUS INFECTION
PT2651965T (en) * 2010-12-15 2019-01-28 Contravir Pharmaceuticals Inc Cyclosporine analogue molecules modified at amino acid 1 and 3
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
WO2012145426A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
WO2013028615A2 (en) * 2011-08-19 2013-02-28 S&T Golbal Inc. Novel cyclosporin derivatives for the treatment and prevention of viral infections
WO2013181339A2 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
US20140213508A1 (en) * 2012-10-19 2014-07-31 Scynexis, Inc. Antiviral macrocycles
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
SG11201507241UA (en) 2013-03-08 2015-10-29 Allergan Inc Cyclosporine a-steroid conjugates
WO2015031381A1 (en) 2013-08-26 2015-03-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
EP3247378B8 (en) 2015-01-09 2023-08-23 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
EP3355930A4 (en) * 2015-10-01 2019-03-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CN111449050A (en) 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 Cyclosporin analogues and uses thereof
EP4054719A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
CN114867735A (en) 2019-11-04 2022-08-05 锐新医药公司 RAS inhibitors
CN115873020A (en) 2019-11-04 2023-03-31 锐新医药公司 RAS inhibitors
PE20231207A1 (en) 2020-09-15 2023-08-17 Revolution Medicines Inc INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU549876B2 (en) * 1977-05-10 1986-02-20 Sandoz Ltd. Dihydrocyclosporin d and isocyclosporin d
EP0056782B1 (en) * 1981-01-09 1984-08-01 Sandoz Ag Novel cyclosporins
GB8407618D0 (en) * 1984-03-23 1984-05-02 Sandoz Ltd Organic compounds
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4685566A (en) * 1985-12-24 1987-08-11 Manville Sales Corporation Sleeve-type carrier

Also Published As

Publication number Publication date
ATE78832T1 (en) 1992-08-15
EP0194972A3 (en) 1989-07-12
AU588860B2 (en) 1989-09-28
DK109486D0 (en) 1986-03-10
DE3686183T2 (en) 1993-01-14
US4771122A (en) 1988-09-13
DE3686183D1 (en) 1992-09-03
JPH0759594B2 (en) 1995-06-28
PH22439A (en) 1988-09-12
JPS61212599A (en) 1986-09-20
DK109486A (en) 1986-09-12
US4703033A (en) 1987-10-27
AU5448586A (en) 1986-09-18
HUT47137A (en) 1989-01-30
GR860646B (en) 1986-07-11
ES8802527A1 (en) 1988-07-16
IL78083A0 (en) 1986-07-31
KR860007285A (en) 1986-10-10
PT82164A (en) 1986-04-01
ES8900141A1 (en) 1989-01-16
ES552855A0 (en) 1989-01-16
ES557619A0 (en) 1988-07-16
EP0194972B1 (en) 1992-07-29
FI860993A0 (en) 1986-03-10
FI860993A (en) 1986-09-12
EP0194972A2 (en) 1986-09-17
NZ215414A (en) 1990-08-28

Similar Documents

Publication Publication Date Title
PT82164A (en) Process for the preparation of new cyclosporines
ES8702926A1 (en) Novel cyclosporins
IE810285L (en) Cyclosporins (cyclic poly-n-methylated undecapeptides) amino¹acids and intermediates
IE881838L (en) Cyclic &#34;peptolides&#34;
CA2042831A1 (en) A recombinant promoter for gene expression in monocotyledonous plants
AU3914289A (en) Immunogenic conjugates comprising cyclosporins
MX9804419A (en) Il-13 receptor polypeptide.
FI903706A0 (en) Process for the preparation of therapeutically active cyclosporine derivatives
IL91691A (en) T cell growth factor, method for the preparation thereof and pharmaceutical compositions containing the same
ZA85441B (en) 6,6-ethylene-15,16-methylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactones,processes for the production thereof,and pharmaceutical preparations containing them
CA2182795A1 (en) Superactive vip antagonists
IL126221A0 (en) Scf analog compositions and methods
AU5557196A (en) High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
NZ320932A (en) Short forms of chemokine b-8
UA26870C2 (en) The method for increasing of protein c production, the method for increasing of modification level thereof
AU7577387A (en) A process for the preparation of human antithrombin III (ATIII), vectors and hosts cells suitable for this purpose, biologically active ATIII obtained in this way, and medicaments containing the latter